N&PD Moderators: Skorpio | someguyontheinternet
Careful guys:
the identity and purity of this compound is open to question. I would begin with lower doses than these (in the range of NBOMe substituted 2Cs) until more reports flow in.
...
It would be really interesting if this were to pan out though, as it would begin to map the SAR of this class of compounds. It would seem at first pass that a ring substitution on the 2-benzyl is key for heightened conformation at the 5ht2a receptor.
ebola
Is there any data/anecdotal evidence that the unsubstituted N-benzyl PEAs have lower efficacy than the parent compounds? How have other N-benzyl PEAs panned out?
The compound was obtained from a reliable source and has an NMR confirming the structure. The titration started at 250 ug, then 500 ug, 1 mg, 2 mg, and 4 mg sublingually, when a threshold was observed, at 2 week intervals. Subsequent trials were at 6, 8, 10, 12 and 14 mg.
Sidenote: What is MDO referring to? CD3O or methylenedioxy?amanitadine said:Everything I have seen seems to point that the bulky oxygen is needed there for the increased efficacy, whether it be a MeO, MDO, or HO group.
^^ Why the raised eyebrow?
I agree the material is quite possibly not what it's claimed to be, but oral inactivity, the duration, and the slightly increased potency over 2C-B suggest it could well be the right stuff.
Plain 2C-B showed a pEC50 of 7.20, with an Emax of 58%.
25B-NBOMe had values of 9.66 and 38%, respectively.
25B-NBOH had values of 9.58 and 35%, respectively.
25B-NBOCF3 is practically inactive, with an Emax of just 6%, and ca. 100fold less affinity to r5HT2A.
25B-NB was not presented in Ralf Heim's thesis; the only (!) publication dealing with this derivative is by Glennon et al. in Journal of Medicinal Chemistry (1994), 37(13): 1929, which presents only affinity but no efficacy data, as was already pointed out by skillet. Extrapolating from what is available, I'd estimate that 25B-NB is probably several orders of magnitude less potent than 25B-NBOX and, therefore, do the results of tryp2fun's bioassays cause a raised eyebrow on my side (see the last paragraph of this post).
Short underline to the above data:
"pEC50" = partial agonistic efficacyMore details how these values are calculated can be found in Jenkinson et al., Pharmacol Rev (1995), 47: 255.
"Emax" = intrinsic activity; both refer to measured by functional in vitro assay using cylindric segments from rat tail arteries (ie. r5-HT2A-receptor data)
"relative potency" refers to 5HT, which is set as 1.
For non-german speakers, who can't read resp. understand Heims's diss, I refer to J Comput Aided Mol Des (2011), 25: 51, which presents an up-to-date SAR-discussion of the results of Elz' group.
Sidenote: What is MDO referring to? CD3O or methylenedioxy?
@tryp2fun: I do not ask for any sources, but please let me point out that the reliability of RC-products is quite doubtful nowadays. Hence, whereever your sample came from, I hope you have some really good reasons to believe that your sample contains indeed what the label states. Would it go to far to ask for for a scan of the NMR-spectrum?
Ahhh, yes, Sir. That looks indeed persuading. How could I miss that oneIn this paper by Nichols, (Mol Pharmacol. 2006 Dec;70(6):1956-64. Epub 2006 Sep 25. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Braden MR, Parrish JC, Naylor JC, Nichols DE.) he compared 2CI, 2CI-NB, and 2CI-NBOM, among others, and found that the affinity of 2CI-NB is about twice that of 2CI, and the efficacy of 2CI-NB is actually higher than 2CI.